AR060873A1 - Derivados biciclicos como inhibidores de cetp - Google Patents

Derivados biciclicos como inhibidores de cetp

Info

Publication number
AR060873A1
AR060873A1 ARP070101992A ARP070101992A AR060873A1 AR 060873 A1 AR060873 A1 AR 060873A1 AR P070101992 A ARP070101992 A AR P070101992A AR P070101992 A ARP070101992 A AR P070101992A AR 060873 A1 AR060873 A1 AR 060873A1
Authority
AR
Argentina
Prior art keywords
substituted
unsubstituted
alkyl
alkoxy
cycloalkyl
Prior art date
Application number
ARP070101992A
Other languages
English (en)
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of AR060873A1 publication Critical patent/AR060873A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Abstract

La presente se refiere además, al uso de los compuestos de la presente para el tratamiento de, demora de progreso para superar, las enfermedades en donde esté involucrada la proteína de transferencia de colesteril-éster. Reivindicacion 1: Un compuesto de la formula (1), en donde el anillo A, que está templado al anillo B, representa un radical aromático carbocíclico insustituido o sustituido; o un radical aromático heterocíclico insustituido o sustituido; en donde Ar representa un radical aromático carbocíclico Insustituido o sustituido; R1 es el elemento -C(=O)-R3, -C(=O)-O-R3, -C(=O)-NR4R5, -S(O)m-R3, -S(O)mN(R4)(R5), siendo m en cada caso el entero 0, 1, o 2 o R1 es Z; Z se selecciona a partir del grupo que consiste en: cicloalquilo monocíclico insustituido o sustituido, o cicloalquenilo monocíclico Insustituido o sustituido, un radical aromático carbocíclico insustituido o sustituido, o un radical heterocíclico insustituido o sustituido; R3 representa Independientemente hidrogeno, alquilo, haloalquilo, cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido; en la fraccion de cicloalquilo, cicloalquil-alquilo insustituido o sustituido; en la fraccion de cicloalquenilo, cicloalquenil-alquilo insustituido o sustituido; un radical aromático carbocíclico insustituido o sustituido, un radical heterocíclico insustituido o sustituido; o, en la fraccion de arilo, aralquilo insustituido o sustituido; R4 y R5, independientemente uno del otro, representan hidrogeno, alquilo, o cicloalquilo, y el alquilo está sustituido por uno o más sustituyentes seleccionados a partir del grupo que consiste en cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido, y un radical heterocíclico insustituido o sustituido; R7 y R8, independientemente uno del otro, representan cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido, o un radical aromático carbocíclico insustituido o sustituido, o un radical heterocíclico insustituido o sustituido; o R4 y R5 son juntos alquileno insustituido o sustituido, o alquileno insustituido o sustituido que está interrumpido por O, NR3, o S; R3' es R3 o -C(=O)- OR3 y m es el entero 0, 1, o 2; X es CR6 o N, e Y es N; o X es N, e Y es CR6; R6 es hidrogeno, halogeno, NO2, CN, OH, alquilo, alcoxi-alquilo, hidroxi-alquilo, halo-alquilo, alcoxilo, alcoxi-alcoxilo, halo-alcoxilo, -C(=O)-R3, -C(=O)-O-R3, - N(R4)(R5), -C(=O)-NR4R5, -S(O)m-R3, -S(O)m-N(R4)(R5), -NR3-S(O)m-N(R4)(R5), siendo m en cada caso el entero 0, 1, o 2; alcanoilo, cicloalquilo insustituido o sustituido, cicloalquenilo insustituido o sustituido; en la fraccion de arilo, aralquilo insustituido o sustituido; y en la fraccion de heterociclilo, heterociclil-alquilo insustituido o sustituido; y en donde el cicloalquilo sustituido, o el cicloalquenilo sustituido, o el alquileno sustituido, está cada uno de los cuales sustituido por uno o más sustituyentes seleccionados a partir del grupo que consiste en alquilo, alcoxilo, -C(=O)-O-R3, -C(=O)-N(alquil)(alquilo), -N(alquil)(alquilo), H2N-C(=O)-, H2N-C(=O)-alquilo--, formilo, formal-alquilo--, cicloalquil-alquilo, un radical aromático carbocíclico, un radical heterocíclico, aralquilo, y heterociclil-alquilo; y en donde un radical aromático carbocíclico, o un radical aromático heterocíclico, o un radical heterocíclico, en la fraccion de arilo es aralquilo insustituido o sustituido, en la fraccion de heterociclilo es heterociclil-alquilo insustituido o sustituido; o los anillos A o Ar, independientemente uno del otro, están insustituidos o sustituidos por uno o más sustituyentes seleccionados a partir del grupo que consiste en halogeno, NO2, CN, OH, alquilo, alcoxi-alquilo, hidroxi-alquilo, halo-alquilo, alcoxilo, alcoxi-alcoxilo, halo-alcoxilo, -C(=O)-R3, -C(=O)-O-R3, -N(R4)(R5), -C(=O)-NR4R5, -S(O)m-R3, -S(O)mN(R4)(R5), -NR3-S(O)m-N(R4)(R5), y alcanoilo, siendo m en cada caso el entero 0, 1, o 2; y cicloalquilo Insustituido o sustituido, cicloalquenilo insustituido o sustituido; en la fraccion de arilo, aralquilo insustituido o sustituido, y en la fraccion de heterociclilo, heterociclil-alquilo insustituido o sustituido; en forma libre o en forma de sal, o una sal del mismo.
ARP070101992A 2006-05-10 2007-05-08 Derivados biciclicos como inhibidores de cetp AR060873A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
AR060873A1 true AR060873A1 (es) 2008-07-16

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070101992A AR060873A1 (es) 2006-05-10 2007-05-08 Derivados biciclicos como inhibidores de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (es)
EP (1) EP2024356A1 (es)
KR (1) KR101172120B1 (es)
AR (1) AR060873A1 (es)
AU (1) AU2007247385B2 (es)
CA (1) CA2650954C (es)
CL (1) CL2007001325A1 (es)
CR (1) CR10420A (es)
EC (1) ECSP088891A (es)
GT (1) GT200800242A (es)
IL (1) IL195010A0 (es)
MA (1) MA30427B1 (es)
MX (1) MX2008014284A (es)
NO (1) NO20084912L (es)
TN (1) TNSN08444A1 (es)
TW (1) TW200813009A (es)
WO (1) WO2007128568A1 (es)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
EP1848430B1 (en) * 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
AU2007247385B2 (en) * 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
CA2650515A1 (en) * 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as cetp inhibitors
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
EP2149563B9 (en) 2007-04-13 2015-04-22 Kowa Company, Ltd. Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2010061621A1 (ja) 2008-11-28 2010-06-03 興和株式会社 ｔｒａｎｓ－｛４－［（アルキルアミノ）メチル］シクロヘキシル｝酢酸エステルの製造方法
AU2010289397B2 (en) * 2009-09-03 2016-05-26 Bioenergenix Heterocyclic compounds for the inhibition of PASK
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8871758B2 (en) 2011-03-08 2014-10-28 Sanofi Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
US8901114B2 (en) 2011-03-08 2014-12-02 Sanofi Oxathiazine derivatives substituted with carbocycles or heterocycles, method for producing same, drugs containing said compounds, and use thereof
RU2609200C2 (ru) 2011-07-08 2017-01-30 Новартис Аг Способ лечения атеросклероза у субъектов с высоким уровнем триглицеридов
MX2014001849A (es) 2011-08-18 2014-10-24 Reddys Lab Ltd Dr Compuestos de amina heterociclicos sustituidos como inhibidores de proteina de transferencia de ester colesterilo (cetp).
CN103958511A (zh) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 作为胆固醇酯转移蛋白(CETP)抑制剂用于治疗动脉粥样硬化的5-苄基氨基甲基-6-氨基吡唑并[3,4-b]吡啶衍生物
AU2013346501B2 (en) * 2012-11-19 2017-07-13 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of CETP inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
WO2014128564A2 (en) * 2013-02-21 2014-08-28 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
UY35670A (es) 2013-07-25 2015-02-27 Novartis Ag Polipéptidos cíclicos para el tratamiento de insuficiencia cardíaca
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
MX2017009534A (es) 2015-01-23 2018-04-10 Novartis Ag Conjugados de acidos grasos y apelina sintetica con mayor vida media.
US20230076506A1 (en) * 2019-12-11 2023-03-09 Ryvu Therapeutics S.A. Heterocyclic compounds as modulators of stimulator of interferon genes (sting)

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6458852B1 (en) * 1999-09-23 2002-10-01 G.D. Searle & Co. Use of substituted N, N-bis-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
EP1325006A2 (en) * 2000-08-07 2003-07-09 Neurogen Corporation Heterocyclic compounds as ligands of the gaba a? receptor
DK1533292T3 (da) * 2002-08-30 2007-06-04 Japan Tobacco Inc Dibenzylaminforbindelse og medicinsk anvendelse deraf
CA2504941C (en) 2002-11-08 2012-06-26 Neurogen Corporation 3-substituted-6-aryl pyridines
EA200501376A1 (ru) 2003-03-28 2006-04-28 Пфайзер Продактс Инк. Производные 1,2,4-замещённых 1,2,3,4-тетрагидро- и 1,2-дигидрохинолинов и 1,2,3,4-тетрагидрохиноксалина в качестве ингибиторов сетр для лечения атеросклероза и тучности
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
WO2005100298A1 (en) 2004-04-13 2005-10-27 Merck & Co., Inc. Cetp inhibitors
JP2008520645A (ja) 2004-11-23 2008-06-19 ファイザー・プロダクツ・インク ジベンジルアミン化合物および誘導体
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
EP1848430B1 (en) * 2004-12-31 2017-08-02 Dr. Reddy's Laboratories Ltd. Novel benzylamine derivatives as cetp inhibitors
KR101184807B1 (ko) 2005-01-06 2012-09-20 톰슨 라이센싱 디지털 광 프로젝션 시스템에서 레인보우 아티팩트를줄이는 방법 및 장치
US20100203504A1 (en) 2005-07-07 2010-08-12 Yoichi Katsumoto Substance-Information Acquisition Method Using Evanescent Light Beam, Substance-Information Measurement Apparatus, Base-Sequence Determination Method and Base-Sequence Determination Apparatus
WO2007008899A2 (en) 2005-07-11 2007-01-18 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
AU2006330072B2 (en) * 2005-12-28 2012-08-02 Dr. Reddy's Laboratories Ltd. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
PE20071025A1 (es) * 2006-01-31 2007-10-17 Mitsubishi Tanabe Pharma Corp Compuesto amina trisustituido
AU2007247385B2 (en) * 2006-05-10 2011-07-14 Novartis Ag Bicyclic derivatives as CETP inhibitors
CA2650515A1 (en) * 2006-05-11 2007-11-22 Novartis Ag Benzylamine derivatives as cetp inhibitors
BRPI0718809A2 (pt) * 2006-11-15 2013-12-03 Novartis Ag Compostos orgânicos
EP2086961A1 (en) * 2006-11-15 2009-08-12 Novartis AG Heterocyclic derivatives as cetp inhibitors

Also Published As

Publication number Publication date
TW200813009A (en) 2008-03-16
EP2024356A1 (en) 2009-02-18
US8410275B2 (en) 2013-04-02
IL195010A0 (en) 2009-08-03
CL2007001325A1 (es) 2008-07-18
AU2007247385B2 (en) 2011-07-14
GT200800242A (es) 2009-04-29
NO20084912L (no) 2009-02-03
AU2007247385A1 (en) 2007-11-15
MX2008014284A (es) 2008-11-18
KR20090017580A (ko) 2009-02-18
KR101172120B1 (ko) 2012-08-10
CA2650954C (en) 2014-02-11
WO2007128568A1 (en) 2007-11-15
US20090227580A1 (en) 2009-09-10
US20120225874A1 (en) 2012-09-06
MA30427B1 (fr) 2009-05-04
TNSN08444A1 (en) 2010-04-14
CR10420A (es) 2009-02-02
ECSP088891A (es) 2008-12-30
US8232403B2 (en) 2012-07-31
CA2650954A1 (en) 2007-11-15

Similar Documents

Publication Publication Date Title
AR060873A1 (es) Derivados biciclicos como inhibidores de cetp
AR043508A1 (es) 1-amino 1-h-imidazoquinolinas y su uso como inmunomoduladores
CO6382110A2 (es) Compuestos para el tratamiento de la hepatitis c.
PE20131165A1 (es) Analogos de carba-nucleosidos sustituidos con 2'-fluoro para tratamiento antiviral
AR062358A1 (es) Isoxasolinas insecticidas
AR043445A1 (es) Triazolcarboxamidas substituidas
AR072906A1 (es) Nucleosidos modificados utiles como antivirales
UY27333A1 (es) Nucleótidos 4` sustituidos
NI201000150A (es) Nuevos derivados de carbazol, inhibidores de hsp90, composiciones que los contienen y utilización.
DOP2002000333A (es) Derivados de acido isoftalico como inhibidores de metaloproteinasas de la matriz
AR063706A1 (es) Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden.
PE20091099A1 (es) Derivados de aminobenzamida como agentes utiles para controlar parasitos animales
BR0010555A (pt) Inibidores de neuraminidases
CO6260141A2 (es) Inhibidores del co-transportador 2 sodio glucosa y metodos para la preparacion de los mismos y sus intermediarios
TW200612195A (en) Oxime derivatives and the use therof as latent acids
BRPI0514841A (pt) inibidores de piridila da sinalização de hedgehog, processo de preparação dos mesmos e composição compreendendo os referidos inibidores
ES2171040T3 (es) Derivados de esteres hidroxiaceticos y su utilizacion como intermediarios de sintesis.
CY1113873T1 (el) Παραγωγα hydroxybenzamide σαν παραγοντες καταστολης της hsp90
UY29393A1 (es) Nuevos derivados de amidas, sales farmacéuticas aceptables, composiciones que los contienen, procedimientos de preparación y aplicaciones.
AR066972A1 (es) Derivados azapeptidicos
AR053206A1 (es) Derivados de isoindoles, composiciones farmaceuticas que los contienen, sus utilizaciones terapeuticas como inhibidores de la actividad de la proteina chaperona hsp90 y su empleo en la preparacion de medicamentos para el tratamiento de diversos tipos de cancer.
DOP2006000017A (es) Pirazolopiridinas y sales de las mismas, una composición farmaceútica que comprende dichos compuestos, un método para prepararlos y su uso
CY1116168T1 (el) Συγκρυσταλλοι και αλατα αναστολεων toy ccr3
AR061438A1 (es) Derivados de entacapone
AR073043A1 (es) Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras.

Legal Events

Date Code Title Description
FB Suspension of granting procedure